Literature DB >> 10979969

Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures.

N S Andersen1, J K Larsen, J Christiansen, L B Pedersen, N S Christophersen, C H Geisler, J Jurlander.   

Abstract

Interaction between CD40 and the CD40 ligand (CD40L) is critical for the survival and proliferation of B cells during immunopoiesis. However, the role of CD40L in the pathogenesis of malignant lymphomas is ambiguous. Primary mantle cell lymphoma (MCL) cells were cultured in the presence of recombinant human CD40L trimer (huCD40LT), and a significant time- and dose-dependent induction of DNA synthesis was observed in thymidine incorporation assays (n = 7, P <.04). The maximal rate of DNA synthesis was reached at huCD40LT doses of 100 ng/mL and above after 4 days of culture, but a significant increase of DNA synthesis was detected already at doses of 1 ng/mL (P =.03). HuCD40LT never inhibited the basal level of DNA synthesis. These findings established 400 ng/mL of huCD40LT for 4 days as standard conditions in the system. Under these conditions, huCD40LT significantly increased the proportion of cells in the S/G(2)/M phases of the cell cycle in 4 of 7 studied cases, while the fraction of apoptotic cells remained unchanged (n = 7). HuCD40LT also induced expression of CD80/B7-1, CD86/B7-2, and CD95/Fas and up-regulated the expression of HLA-DR (n = 6). With the use of bromodeoxyuridine incorporation in triple-color flow cytometric analysis, it was found that huCD40LT induced cell-cycle progression in light chain-restricted cells only, of which a median of 14% (range, 0.5% to 29%; n = 4) returned to G(0/1) phase DNA content after bromodeoxyuridine incorporation, demonstrating completion of at least one cell cycle in the presence of huCD40LT. Thus, primary clonal MCL cells are activated and can proliferate in the presence of huCD40LT as a single agent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979969

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 2.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

Review 3.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.

Authors:  Monika Anna Grygorowicz; Ilona Sara Borycka; Eliza Nowak; Ewa Paszkiewicz-Kozik; Grzegorz Rymkiewicz; Katarzyna Błachnio; Marzena Biernacka; Mateusz Bujko; Jan Walewski; Sergiusz Markowicz
Journal:  Clin Exp Med       Date:  2016-03-10       Impact factor: 3.984

5.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

6.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

7.  CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies.

Authors:  Daisuke Ito; Aric M Frantz; Christina Williams; Rachael Thomas; Robert C Burnett; Anne C Avery; Matthew Breen; Nicola J Mason; Timothy D O'Brien; Jaime F Modiano
Journal:  Leuk Lymphoma       Date:  2012-02-03

8.  Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.

Authors:  Norihiko Kawamata; John Chen; H Phillip Koeffler
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113

9.  SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.

Authors:  Patricia Balsas; Luis Veloza; Guillem Clot; Marta Sureda-Gómez; Marta-Leonor Rodríguez; Christos Masaoutis; Gerard Frigola; Alba Navarro; Silvia Beà; Ferran Nadeu; Eva Giné; Armando López-Guillermo; Antonio Martínez; Inmaculada Ribera-Cortada; Pablo Engel; Leticia Quintanilla-Martínez; Wolfram Klapper; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

10.  Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma.

Authors:  M Reis-Sobreiro; G Roué; A Moros; C Gajate; J de la Iglesia-Vicente; D Colomer; F Mollinedo
Journal:  Blood Cancer J       Date:  2013-05-31       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.